Cerevance to Participate at the 3rd Annual Needham Biotech Private Company Forum
October 10, 2023 08:00 ET
|
Cerevance
BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing precision novel therapeutics for central nervous system...
Cerevance to Participate at the 2023 Life Sciences Private Company Showcase
October 04, 2023 08:00 ET
|
Cerevance
BOSTON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing precision novel therapeutics for central nervous system...
Cerevance Announces Presentation at the 36th European College of Neuropsychopharmacology Congress
October 02, 2023 08:00 ET
|
Cerevance
BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel precision therapeutics for central nervous system...
Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease
September 19, 2023 08:30 ET
|
Cerevance
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on advancing novel, precision neuroscience therapeutics for central...
Cerevance to Present During the 6th Annual LSX World Congress USA
September 06, 2023 08:30 ET
|
Cerevance
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on advancing novel, precision neuroscience therapeutics for central...
Cerevance Announces Presentation at the 22nd Society of Chemical Industry / Royal Society of Chemistry Medicinal Chemistry Symposium
August 31, 2023 08:30 ET
|
Cerevance
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on advancing novel, precision neuroscience therapeutics for central...
Fierce Biotech Names Cerevance a “Fierce 15” Biotech Company of 2023
August 28, 2023 08:30 ET
|
Cerevance
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on advancing novel, precision neuroscience therapeutics for central...
Cerevance Announces Presentation at the Alzheimer’s Association International Conference
July 10, 2023 08:30 ET
|
Cerevance
BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS)...
Cerevance Announces Presentation at the XVI European Meeting on Glial Cells in Health and Disease
June 28, 2023 08:30 ET
|
Cerevance
BOSTON, June 28, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS)...
Cerevance Announces Presentation at the Gordon Research Conference: Amyotrophic Lateral Sclerosis and Related Motor Neuron Diseases
June 26, 2023 08:30 ET
|
Cerevance
BOSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS)...